Tarmo Korpela

Tarmo Korpela

Auto-generated profile, based on publicly available information

Tarmo Korpela

Department of Cardiothoracic Surgery, Heart Centre, Kuopio University Hospital (KUH) , Kuopio 70210

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
TKTarmo Korpela
Tarmo Korpela
SKS Petteri Kauhanen
S Petteri Kauhanen
EKElina Kariniemi
Elina Kariniemi
PSPetri Saari
Petri Saari
TLTimo Liimatainen
Timo Liimatainen
MHMarja Hedman
Marja Hedman
Our goal was to evaluate whether four-dimensional (4D) flow magnetic resonance imaging (MRI) can predict the growth rate of dilatation of the ascending aorta (AA) in patients with a tricuspid, normally functioning aortic valve. In this prospective clinical study, aortic 4D flow MRI was performed at the Kuopio University Hospital on 30 patients diagnosed with AA dilatation (maximum diameter >40 mm) between August 2017 and July 2020. The MRI was repeated after a 1-year follow-up, with AA dimensions and 4D flow parameters analysed retrospectively at both time points. The standard error of measurement was used to assess the statistical significance of the growth rate of AA dilatation. Flow displacement (FD) was transformed to a class-scaled parameter using FD ≥5% as a threshold. Statistically significant growth [median 2.1 mm (1.5–2.2 mm); P = 0.03] was detected in 6 male patients (20%); the AA diameter remained unchanged [0.2 mm (−0.3 to 0.9 mm)] in 24 patients (80%). An increased FD at the baseline was associated with significant growth during the 1-year follow-up in the proximal AA. An association was detected between decreased total wall shear stress and significant aortic growth in the inner curve of the sinotubular junction [529 mPa (449–664 mPa) vs 775 mPa (609–944 mPa); P = 0.03] and the anterior side of the proximal aortic arch [356 mPa (305–367 mPa) vs 493 mPa (390–586 mPa); P < 0.001]. FD and decreased wall shear stress seem to be associated with significant growth of AA dilatation at the 1-year follow-up. Thus, 4D flow MRI might be useful in assessing risk for AA diameter growth in patients with a tricuspid aortic valve.

25 November 2024 in Scandinavian Journal of Surgery
Verified
Journal Article
Open access
TKTarmo Korpela
Tarmo Korpela
ESElina Salomaa
Elina Salomaa
PKPetteri Kauhanen
Petteri Kauhanen
TSTuomas Selander
Tuomas Selander
MHMarja Hedman
Marja Hedman
AHAnnastiina Husso
Annastiina Husso
Background and Aims: To investigate whether, alongside aortic dilatation, ascending aortic (AA) elongation is associated with the increased risk for aortic dissection. Methods: This retrospective study included patients treated for Stanford type A aortic dissection (n = 102) in Kuopio University Hospital between 2009 and 2022, patients with AA dilatation (maximal diameter > 40 mm) (n = 134), and healthy controls (n = 191). AA length and dimensions were measured from aortic computed tomography angiography (CTA) images. AA length was defined as the distance between the aortic annulus and the origin of the brachiocephalic trunk. Results: After adjusting the AA length to the patients’ age, height, body surface area (BSA), sex, and maximal diameter, the dissected aortas were 14 mm longer than in the healthy controls and 5 mm longer than in the dilated non-dissected aortas (p < 0.001). The dilated non-dissected aortas were 8 mm longer than in the healthy controls (p < 0.001). In the dissection cohort, 25/102 (25%) patients had maximal AA diameter < 55 mm and 16/102 (16%) patients had maximal AA diameter ⩾ 55 mm together with AA length > 110 mm. By combining 110 mm AA length and < 55 mm diameter, 58% of the dissection patients would have been identified instead of using solely AA diameter ⩾ 55 mm as a cut-off criterion, based on which only 33% patients met the indication for elective surgery. Conclusion: AA length seemed to have an association with acute type A dissection, and therefore, it could be an additional tool in identifying patients who may benefit from preventive aortic surgery.

27 February 2026 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
IKIida-Mari Kotanen
Iida-Mari Kotanen
TSTuomas Selander
Tuomas Selander
COChristian Olsson
Christian Olsson
AFAnders Franco-Cereceda
Anders Franco-Cereceda
DMDavid Marlevi
David Marlevi
MHMarja Hedman
Marja Hedman
Objectives: The majority of acute type A aortic dissections (ATAADs) occur at ascending aortic dimensions and growth rates below current preventive surgery thresholds. This study aimed to investigate the risk of ATAAD based on the ascending aortic diameter, length, and their growth rates. Methods: The ascending aortic diameters and lengths were measured using repeated pre-dissection computed tomography and magnetic resonance imaging acquired during follow-up to evaluate their growth patterns and rates prior to the ATAAD onset. Measurements and growth rates were used to develop the risk function for the ATAAD risk assessment. Results: Ascending aortic aneurysm patients (n = 116) were divided into ATAAD (n = 30) and non-ATAAD groups (n = 86). Almost half of the ATAAD patients (46.7%) did not exceed the current preventive surgery thresholds based on the dimensions. A diameter growth rate of 3 mm/year was extremely rare (2.6%). The risk function was introduced in this study, and it could be used to predict the 5-year risk of ATAAD with excellent confidence (area under the curve [AUC] value of 0.83 (95% CI [0.54-0.98])). Conclusions: The combination of ascending aortic diameter and length and their growth rates offers a valuable tool for assessing the risk of an ATAAD. Almost half of the ATAAD patients fall below the established thresholds when assessed using only ascending aortic dimensions. These findings suggest that preventive surgery thresholds may benefit from including all four parameters: ascending aortic diameter and length and their growth rates. Clinical registration number: DilAo-Trial ClinicalTrials.gov ID 5063566